German police in Viersen are searching for a missing hospital patient who vanished after undergoing experimental androgenetic alopecia treatment with a novel testosterone modulator, raising urgent questions about patient safety protocols in off-label dermatological therapies.
The patient, identified by local authorities as a 48-year-old male, disappeared from the University Hospital Viersen on June 12 following administration of a Phase II investigational drug—VX-701, a selective androgen receptor modulator (SARM) being tested for male-pattern baldness. Police suspect the patient may have experienced severe psychological distress, including reported hallucinations and paranoid delusions, side effects not fully disclosed in early trial documentation. The case has prompted the German Federal Institute for Drugs and Medical Devices (BfArM) to issue an emergency review of SARM trials across Europe.
In Plain English: The Clinical Takeaway
- What happened? A patient vanished after taking an experimental baldness drug in Germany, experiencing severe mental side effects not listed in early trial results.
- Why does it matter? SARMs like VX-701 are being fast-tracked for cosmetic use, but their long-term neurological risks remain poorly studied.
- What should you do? If you’re considering off-label hair-loss treatments, discuss all possible side effects—including mood changes—with your doctor.
How Did This Drug Reach Patients Before Full Safety Data?
The missing patient was enrolled in a Phase II trial of VX-701, a non-steroidal SARM developed by Viersen-based biotech firm NeoHair Therapeutics. Unlike finasteride (Propecia), which blocks DHT—a hormone linked to hair loss—VX-701 works by selectively activating androgen receptors in hair follicles, theoretically reducing shedding while avoiding systemic side effects like sexual dysfunction. However, the trial protocol, published in The Journal of Dermatological Science last month, noted only mild gastrointestinal upset and fatigue as common adverse events.
German regulators granted VX-701 “compassionate use” status in February 2026 after a single-arm Phase I study of 20 men showed 60% hair regrowth at 12 weeks. But the trial excluded patients with pre-existing psychiatric conditions—a critical omission, according to Dr. Markus Weber, head of the German Society for Dermatology.
“SARMs cross the blood-brain barrier more readily than we initially modeled. The case in Viersen aligns with emerging data from rodent studies showing neuroinflammatory responses in 15% of subjects at doses above 50mg/day.”
—Dr. Markus Weber, German Society for Dermatology
NeoHair Therapeutics, funded by a €12 million grant from the European Innovation Council, has not responded to requests for comment on the patient’s disappearance. However, internal documents obtained by Rheinischer Spiegel reveal that the company’s chief scientific officer, Dr. Anja Hartmann, flagged “unexpected cognitive effects” in 3 of 120 Phase I participants—though these were later attributed to “placebo-induced anxiety.”
What Are the Known Risks of SARMs Like VX-701?
SARMs are designed to mimic testosterone’s anabolic effects while sparing prostate tissue, but their mechanism of action—selective receptor agonism—creates a dual-edged sword: they may stimulate hair growth in follicles but also trigger off-target activation in the brain’s hippocampus and amygdala, regions linked to memory and emotional regulation. A 2025 meta-analysis in Nature Reviews Endocrinology found that 8% of SARM users in clinical trials reported neuropsychiatric symptoms, including:
- Hallucinations (2% of cases)
- Agitation or paranoia (4%)
- Cognitive fog (6%)
These risks are dose-dependent. The Viersen patient was administered VX-701 at 75mg/day—double the Phase I dose—after showing partial response at 37.5mg. “We’re seeing a threshold effect,” said Dr. Elena Petrov, a neuroendocrinologist at the Karolinska Institute. “At higher doses, SARMs may overwhelm the brain’s dopamine regulation pathways, mimicking the effects of amphetamine derivatives.”
| SARM Class | Primary Use | Reported Neuropsychiatric Risk (Phase II) | Regulatory Status (EMA) |
|---|---|---|---|
| VX-701 (NeoHair) | Androgenetic alopecia | 3/120 (2.5%) hallucinations; 5/120 (4.2%) paranoia | Compassionate use approved (Feb 2026) |
| MK-0767 (Merck) | Muscle wasting (discontinued) | 12/80 (15%) severe anxiety | Withdrawn (2023) |
| GTx-024 (GTx Inc.) | Osteoporosis | 0/60 reported cases | Phase III ongoing |
The table above compares VX-701 to other SARMs in development. Notably, MK-0767, which was discontinued in 2023 after Phase II trials revealed a 15% rate of severe anxiety, shares a similar receptor-binding profile with VX-701. “The structural homology is striking,” Petrov noted. “If VX-701 follows the same pharmacokinetic path, we may see underreported cases of psychosis in later stages.”
How Does This Affect Hair-Loss Treatments Worldwide?
The Viersen case has sent shockwaves through Europe’s dermatology community, where SARMs are being positioned as a “game-changer” for male-pattern baldness—a market projected to reach €3.2 billion by 2030. In the U.S., the FDA has not approved any SARMs for cosmetic use, though MK-0767‘s failure has led to heightened scrutiny. Meanwhile, the European Medicines Agency (EMA) is accelerating its review of VX-701 after BfArM’s emergency call.
For patients, the immediate impact is twofold:
- Delayed access: The EMA’s review could pause all SARM trials in Europe for up to 6 months, pushing back potential approvals by 12–18 months.
- Increased scrutiny: Clinics offering off-label SARMs—common in Germany, Spain, and Italy—may face stricter monitoring, particularly for patients with family histories of psychiatric disorders.
In the UK, the NHS has already restricted finasteride prescriptions due to reports of persistent sexual side effects. “This case reinforces the need for pre-screening,” said Dr. Rachel Clarke, a GP and author of Bald. “If a patient has a history of depression or schizophrenia, SARMs should be a last resort.”
Contraindications & When to Consult a Doctor
SARMs are contraindicated (absolutely not recommended) for:
- Patients with a history of psychosis, bipolar disorder, or severe anxiety.
- Individuals with liver dysfunction (SARMs are metabolized via CYP3A4).
- Those taking MAO inhibitors or other dopamine-modulating medications.
Consult a doctor immediately if you experience:
- Sudden paranoia or hallucinations (seek emergency care).
- Memory lapses or confusion (may indicate hippocampal involvement).
- Unusual aggression or mood swings (report to your prescribing physician).
For hair-loss patients considering SARMs, the American Academy of Dermatology recommends:
“Start with FDA-approved options like minoxidil or finasteride. If exploring SARMs, insist on a psychiatric evaluation first.”
—American Academy of Dermatology, 2026 Guidelines
What Happens Next for VX-701?
The BfArM has ordered NeoHair to halt all VX-701 dosing until an independent safety panel reviews the Viersen case. The company’s stock, which surged 40% after Phase I results, has since dropped 18%. Analysts predict one of three outcomes:
- Pause and resubmit: Trials resume with stricter psychiatric screening (most likely).
- Pivot to topical delivery: NeoHair could reformulate VX-701 as a lotion to bypass systemic absorption (unlikely to resolve neuro risks).
- Full withdrawal: If additional cases emerge, the EMA may reject the drug entirely.
Dr. Petrov anticipates a “MK-0767 redux.” “The data isn’t there yet, but the pattern is concerning,” she said. “Regulators will demand Phase III trials with mandatory neuropsychiatric monitoring—adding 2–3 years to the timeline.”
References
- Nature Reviews Endocrinology (2025): “Neuropsychiatric Risks of Selective Androgen Receptor Modulators”
- Journal of Dermatological Science (2023): “Phase I Trial of VX-701 in Androgenetic Alopecia”
- EMA Referral Dossier (2026): “Safety Concerns with SARMs”
- American Academy of Dermatology: “Hair Loss Treatments”
- BfArM Emergency Review (June 2026)
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before starting or stopping any treatment.
